We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+10.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$235M
AUM Growth
+$15.3M
Cap. Flow
+$7.44M
Cap. Flow %
3.16%
Top 10 Hldgs %
31.26%
Holding
99
New
22
Increased
25
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$6.47M
2
CNC icon
Centene
CNC
+$4.68M
3
SYK icon
Stryker
SYK
+$4.47M
4
AET
Aetna Inc
AET
+$4.31M
5
GSK icon
GSK
GSK
+$4.18M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$7.97M
2
ABBV icon
AbbVie
ABBV
+$5.99M
3
A icon
Agilent Technologies
A
+$3.59M
4
PFE icon
Pfizer
PFE
+$2.77M
5
ELGX
Endologix Inc
ELGX
+$2.66M

Sector Composition

Rank Sector Weight
1 Healthcare 62.78%
2 Financials 4.02%
3 Industrials 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
51
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.65M 0.7%
+18,000
New +$1.52M
ATRC icon
52
AtriCure
ATRC
$2.12B
$1.56M 0.66%
110,098
-13,352
-11% -$204K
IVC
53
CALL
DELISTED
Invacare Corporation
IVC
$1.52M 0.64%
125,000
– –
VIVE
54
DELISTED
VIVEVE MED INC
VIVE
$1.51M 0.64%
+369
New +$1.72M
NUVA
55
DELISTED
NuVasive, Inc.
NUVA
$1.49M 0.63%
+25,000
New +$1.35M
DCOY
56
Decoy Therapeutics
DCOY
$2.04M
– –
0
– –
SGYP
57
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.33M 0.57%
350,000
-222,800
-39% -$755K
XENT
58
CALL
DELISTED
Intersect ENT, Inc
XENT
$1.29M 0.55%
+100,000
New +$1.57M
ISEE
59
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.28M 0.54%
+25,000
New +$1.24M
WMGIZ
60
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$740K 0.31%
586,936
– –
ADYX
61
DELISTED
Adynxx Inc
ADYX
$653K 0.28%
9,717
+1,193
+14% +$71.3K
FOMX
62
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$648K 0.28%
102,000
– –
TNXP icon
63
Tonix Pharmaceuticals
TNXP
$201M
– –
0
– –
RCKT icon
64
Rocket Pharmaceuticals
RCKT
$397M
$558K 0.24%
18,750
– –
FPRX
65
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$548K 0.23%
13,250
– –
ZGNX
66
DELISTED
Zogenix, Inc.
ZGNX
$473K 0.2%
58,750
– –
ALDX icon
67
Aldeyra Therapeutics
ALDX
$91.1M
$441K 0.19%
77,500
+20,000
+35% +$112K
DMK
68
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$435K 0.18%
2,221
+1,071
+93% +$494K
NDRM
69
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$401K 0.17%
+24,683
New +$416K
IMMU
70
DELISTED
Immunomedics Inc
IMMU
$271K 0.12%
116,743
+44,243
+61% +$148K
OCRX
71
DELISTED
Ocera Therapeutics, Inc.
OCRX
$249K 0.11%
131,000
– –
ADMA icon
72
ADMA Biologics
ADMA
$2.18B
$217K 0.09%
+36,500
New +$256K
NVCN
73
DELISTED
Neovasc Inc.
NVCN
$135K 0.06%
+10
New +$494K
STDY
74
DELISTED
SteadyMed Ltd
STDY
$94K 0.04%
+28,758
New +$100K
A icon
75
Agilent Technologies
A
$42B
– –
-90,000
Closed -$3.59M
1 2
3
4

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q2 2016 Portfolio in Review

As of Q2 2016, Pura Vida Investments held 99 positions worth $235M, up 7% from $220M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Pura Vida Investments deployed $7.44M of net new capital in Q2 2016, opening 22 new positions and adding to 25 existing holdings. Its largest new stake was Medtronic: 80,000 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 60% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Allergan plc, an estimated $7.97M trimmed.

  • Pura Vida Investments's largest Q2 2016 buy was Medtronic: 80,000 shares worth $6.94M.
  • Pura Vida Investments added most to Centene in Q2 2016, an estimated $4.68M increase.
  • Pura Vida Investments's biggest Q2 2016 reduction was Allergan plc, cutting an estimated $7.97M.
  • Pura Vida Investments fully exited AbbVie in Q2 2016, selling an estimated $5.99M.
  • Pura Vida Investments's ten largest holdings make up 31% of its $235M portfolio in Q2 2016.
  • Pura Vida Investments opened 22 new positions and closed 25 in Q2 2016.
  • Pura Vida Investments's portfolio value rose 7% quarter-over-quarter to $235M.

Based on Pura Vida Investments's 13F filing for Q2 2016, filed 15 Aug 2016.